- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Kathy Oubre Previews Festival of Biologics 2022 Discussions
Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, previews her upcoming presentations at the Festival of Biologics conference.
Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, previews her upcoming presentations at the Festival of Biologics conference.
Transcript
You are going to be speaking at Terrapinn’s Festival of Biologics conference happening in March. What are you going to be discussing and what can audiences look forward to?
I will be doing a panel presentation with Sean McGowan [AmerisourceBergen]; Bhavesh Shah, RPh, BCOP; and Craig [Burton] from AAM [Association for Accessible Medicines]. We're doing the keynote on the first day, and we'll be discussing present and future considerations for the biosimilar industry. We're going to be doing a much broader kind of a 30,000-foot discussion, and in that, will talk about the current biosimilars market products and some industry milestones: where we started, where we are now, and we are going to be looking forward. We will discuss what we see coming as far as launches and what's going to be happening in the space within the next 6 months, the next year, the next 5 years. And then we'll be having probably a fairly robust discussion regarding the regulatory constraints and some policy implications around biosimilars.
Additionally, on the third day, I will be doing a panel presentation with Melody Chang, RPh, MBA, BCOP, at AON [American Oncology Network] and we'll be discussing the importance of biosimilars within the oncology landscape and kind of a crystal ball discussion of where we see biosimilars in oncology moving forward.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
A Long Time Coming: Dr Sophia Humphreys Details What’s Coming Down the Biosimilar Pipeline
March 23rd 2023In the wake of adalimumab biosimilars hitting the US market, Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health, hyped up the current biosimilar market trends and the other products coming down the pipeline during her talk at the Festival of Biologics.
Published Data Coupled With Real-world Evidence Show Safety of Biosimilar-to-Biosimilar Switching
March 22nd 2023At the Festival of Biologics, Hillel Cohen, the executive director of scientific affairs at Sandoz, shared the current body of literature on biosimilar-to-biosimilar switching, saying that although there isn’t much published data, the vast real-world experience demonstrates the safety of this type of medication switch.
